PYC - Ticker AI Digest

Physiomics Plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (PYC) 1
PYC 06:01
Physiomics Plc
Platform Implementation and Partnership Expansion
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Physiomics plc, a mathematical modelling and data science company, announces the successful implementation of its personalised dosing software onto the DoseMeRx platform, expanding its partnership with DoseMe. The software, developed with grant funding, aims to optimise dosing decisions for cancer chemotherapies and mitigate the risk of infection and hospitalisation. The partnership combines Physiomics oncology expertise with DoseMes experience in delivering dosing tools, with the eventual goal of commercialising the software. The companies have signed non-binding Heads of Terms to expand their collaboration beyond the current software, focusing on development, commercialisation, and co-development of novel dosing software tools. Physiomics CEO, Dr Peter Sargent, expresses excitement about the expanded partnership and the potential for applying their modelling expertise to new dosing software. Dr Sharmeen Roy, Chief Strategy and Science Officer of DoseMe, highlights the alignment of the collaboration with their focus on advancing transitional precision dosing.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 2
PYC 06:01
Physiomics Plc
Contract Award
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Physiomics PLC, a mathematical modelling and data science company, has been awarded a new contract with an existing client. The £98,600 project will focus on PK/PD modelling and simulation to support the preclinical-to-clinical transition of a non-oncology therapeutic. This highlights Physiomics integrated approach to drug development and its ability to provide insights across the entire drug development lifecycle. The project will be delivered over 18 months, with Physiomics providing valuable insights to inform and accelerate the clients drug development programme. This contract showcases Physiomics expertise in de-risking decision-making and optimising research design, reinforcing its position as a trusted partner in the biotech and pharma industries.
PYC 06:01
Physiomics Plc
New Head of Biometrics and Two Contracts Awarded
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Physiomics plc, a mathematical modelling and data science company, announces the appointment of Jesse Thissen as Head of Biometrics and the signing of two biometrics contracts worth £111,000. The contracts involve providing biostatistical consulting and statistical programming services for a UK-based biopharmaceutical company developing immunotherapies. Jesse Thissen, with experience in Large Pharma and Biotech, will lead the companys new Biometrics service line, focusing on biostatistics and statistical programming. The addition of Biometrics capabilities is expected to transform Physiomics business, enabling broader solutions and faster growth. The companys CEO, Dr. Peter Sargent, emphasizes the importance of Biometrics in drug development and its complementarity with modelling and simulation, allowing them to offer integrated solutions and target a larger market.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 1
PYC 06:01
Physiomics Plc
Platform Implementation and Partnership Expansion
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Physiomics plc, a mathematical modelling and data science company, announces the successful implementation of its personalised dosing software onto the DoseMeRx platform, expanding its partnership with DoseMe. The software, developed with grant funding, aims to optimise dosing decisions for cancer chemotherapies and mitigate the risk of infection and hospitalisation. The partnership combines Physiomics oncology expertise with DoseMes experience in delivering dosing tools, with the eventual goal of commercialising the software. The companies have signed non-binding Heads of Terms to expand their collaboration beyond the current software, focusing on development, commercialisation, and co-development of novel dosing software tools. Physiomics CEO, Dr Peter Sargent, expresses excitement about the expanded partnership and the potential for applying their modelling expertise to new dosing software. Dr Sharmeen Roy, Chief Strategy and Science Officer of DoseMe, highlights the alignment of the collaboration with their focus on advancing transitional precision dosing.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 3
PYC 06:01
Physiomics Plc
Platform Implementation and Partnership Expansion
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Physiomics plc, a mathematical modelling and data science company, announces the successful implementation of its personalised dosing software onto the DoseMeRx platform, expanding its partnership with DoseMe. The software, developed with grant funding, aims to optimise dosing decisions for cancer chemotherapies and mitigate the risk of infection and hospitalisation. The partnership combines Physiomics oncology expertise with DoseMes experience in delivering dosing tools, with the eventual goal of commercialising the software. The companies have signed non-binding Heads of Terms to expand their collaboration beyond the current software, focusing on development, commercialisation, and co-development of novel dosing software tools. Physiomics CEO, Dr Peter Sargent, expresses excitement about the expanded partnership and the potential for applying their modelling expertise to new dosing software. Dr Sharmeen Roy, Chief Strategy and Science Officer of DoseMe, highlights the alignment of the collaboration with their focus on advancing transitional precision dosing.
PYC 06:01
Physiomics Plc
Contract Award
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Physiomics PLC, a mathematical modelling and data science company, has been awarded a new contract with an existing client. The £98,600 project will focus on PK/PD modelling and simulation to support the preclinical-to-clinical transition of a non-oncology therapeutic. This highlights Physiomics integrated approach to drug development and its ability to provide insights across the entire drug development lifecycle. The project will be delivered over 18 months, with Physiomics providing valuable insights to inform and accelerate the clients drug development programme. This contract showcases Physiomics expertise in de-risking decision-making and optimising research design, reinforcing its position as a trusted partner in the biotech and pharma industries.
PYC 06:01
Physiomics Plc
New Head of Biometrics and Two Contracts Awarded
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Physiomics plc, a mathematical modelling and data science company, announces the appointment of Jesse Thissen as Head of Biometrics and the signing of two biometrics contracts worth £111,000. The contracts involve providing biostatistical consulting and statistical programming services for a UK-based biopharmaceutical company developing immunotherapies. Jesse Thissen, with experience in Large Pharma and Biotech, will lead the companys new Biometrics service line, focusing on biostatistics and statistical programming. The addition of Biometrics capabilities is expected to transform Physiomics business, enabling broader solutions and faster growth. The companys CEO, Dr. Peter Sargent, emphasizes the importance of Biometrics in drug development and its complementarity with modelling and simulation, allowing them to offer integrated solutions and target a larger market.

AI Crunch

Single-Ticker AI Crunch
PYC signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Physiomics Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full PYC AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for PYC on 2025-07-10.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
2266043
Enterprise Value
1699233
Public Float
48.12
Broker Target
0.2
Shares Out
453208718
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BDR6W943
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-04
Net Debt
-461242.0
Cash
461242.0
EPS
-
Net Income
-415254.0
Revenue
784005.0
Enterprise Value
1699233
Trailing PE
-
Forward PE
6.1652
Price Sales TTM
2.2477
Price Book MRQ
5.766
EV Revenue
2.1081
EV EBITDA
-8.7624

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
21.2662
Institutions As Of
2026-03-24
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
1
Sale Director Dealing
0
Purchase TR1
3
Sale TR1
2
Broker Coverage Rows
0
Institution Holders Tracked
4
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit PYC.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-07-10 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Physiomics Plc has fresh news flow feeding the chart narrative.
AI Charts Studio
PYC Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-07-10 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -8.33%
RSI Gauge
Price Change
AI Forecast